Bli medlem
Bli medlem

Du är här


Immune Pharmaceuticals: G. John Mohr Joins Immune Pharmaceuticals as Senior Vice President of Business Development


New role strengthens Immune's ability to advance portfolio through
strategic partnering.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company") a
clinical-stage company developing novel therapies for the treatment of
immuno- inflammatory diseases and cancer today announced that it has
appointed G. John Mohr as senior vice president of business development and
a member of the Immune executive committee. In this role, John Mohr will be
responsible for overseeing alliance and business development activities for
the Company.

John Mohr has served in the pharmaceutical business for over twenty years
in multiple functions including business development, strategic planning
and marketing. Prior to joining Immune, he was managing director at the
consulting firm BioAsset Advisors advising public and private companies on
strategic partnering and licensing activities.

"We are pleased to have John join us to lead our business development and
partnering activities," said Dr. Daniel Teper, CEO of Immune. "As a
senior-level executive John has been involved in many significant
transactions and brings valuable deal execution experience to our team.
John is well acquainted with our Company's lead program, bertilimumab, and
served as an advisor to Immune when at the time we acquired the license.
John shares our vision for bertilimumab and will be leading our efforts to
maximize strategic transactions for our entire portfolio."

John Mohr previously served as senior vice president with CV Therapeutics,
a publicly traded drug company focused on innovative cardiovascular
therapeutics, and he lead several major global transactions with Menarini
and Astellas. In addition, he was instrumental in the $1.4 billion sale of
the company to Gilead in 2009. Prior to that, he was the chief operating
officer for Topigen Pharmaceuticals, a clinical stage company developing
innovative therapeutics in the respiratory field. He was senior vice
president with Atherogenics and President of Fournier Pharma US, where he
delivered billion dollar deals with AstraZeneca and Abbott. John is a
graduate of Drexel University in Finance and Accounting, a CPA and
certified licensing executive.

"This is a pivotal time to join the Company," said John Mohr. "In addition
to the exciting opportunity with bertilimumab progressing in the clinic,
Immune has several other valuable programs to offer for partnering. I look
forward to adding value to Immune and working with the team."

NEW YORK, December 7, 2015

Christine J. Petraglia
Director, Investor Relations
IMMUNE Pharmaceuticals, Inc.

The following documents can be retrieved from beQuoted
Immune Pharmaceuticals Pressrelease 2015-12-07.pdf

About Immune Pharmaceuticals:

Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to
treating and developing novel, highly-targeted antibody therapeutics to
improve the lives of patients with inflammatory diseases and cancer.
Immune's lead product candidate, bertilimumab, is in phase II clinical
development for moderate-to-severe ulcerative colitis as well as for
bullous pemphigoid, an orphan auto-immune dermatological condition. Other
indications being considered for development include atopic dermatitis,
Crohn's disease, severe asthma and NASH (an inflammatory liver disease).
Immune recently expanded its portfolio in immuno-dermatology with topical
nano-formulated cyclosporin A for the treatment of psoriasis and atopic
dermatitis. Immune's oncology pipeline includes, bi-specific antibodies
nanotherapeutics, including NanomAbs®, and several mid-to late stage small
molecules .Immune's non- core pipeline includes AmiKet™, a late clinical
stage drug candidate for the treatment of neuropathic pain. For more
information, visit Immune's website at

Forward-Looking Statements

This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. You are urged to consider statements that include the words
"may," "will," "would," "could," "should," "believes," "estimates,"
"projects," "potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of those words
or other comparable words to be uncertain and forward-looking. Such
forward-looking statements include statements that express plans,
anticipation, intent, contingency, goals, targets, future development and
are otherwise not statements of historical fact. These statements are based
on our current expectations and are subject to risks and uncertainties that
could cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by such
forward-looking statements. Factors that may cause actual results or
developments to differ materially include, but not limited to: the risks
associated with the adequacy of our existing cash resources and our ability
to continue as a going concern; the risks associated with our ability to
continue to meet our obligations under our existing debt agreements; the
risk that clinical trials for bertilimumab or AmiKet™ will not be
successful; the risk that bertilimumab, AmiKet or compounds arising from
our NanomAbs program will not receive regulatory approval or achieve
significant commercial success; the risk that we will not be able to find a
partner to help conduct the Phase III trials for AmiKet on attractive
terms, on a timely basis or at all; the risk that our other product
candidates that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later-stage
clinical trials; the risk that we will not obtain approval to market any of
our product candidates; the risks associated with dependence upon key
personnel; the risks associated with reliance on collaborative partners and
others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating
losses since our inception; the highly competitive nature of our business;
risks associated with litigation; and risks associated with our ability to
protect our intellectual property. These factors and other material risks
are more fully discussed in our periodic reports, including our reports on
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and
Exchange Commission. You are urged to carefully review and consider the
disclosures found in our filings, which are available at
or at
. You are cautioned not to place
undue reliance on any forward- looking statements, any of which could turn
out to be wrong due to inaccurate assumptions, unknown risks or
uncertainties or other risk factors. We expressly disclaim any obligation
to publicly update any forward looking statements contained herein, whether
as a result of new information, future events or otherwise, except as
required by law.

Författare SIX news

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.